scholarly journals Patterns of co-morbidity of eating disorders and substance use in Swedish females

2009 ◽  
Vol 40 (1) ◽  
pp. 105-115 ◽  
Author(s):  
T. L. Root ◽  
E. M. Pisetsky ◽  
L. Thornton ◽  
P. Lichtenstein ◽  
N. L. Pedersen ◽  
...  
Keyword(s):  
Eating Disorders ◽  
Substance Use ◽  
Eating Disorder ◽  
Alcohol Abuse ◽  
Illicit Drugs ◽  
Large Population ◽  
Population Based ◽  
Polysubstance Use ◽  
Co Morbidity ◽  
Diet Pill

BackgroundLittle is known about the association of eating disorder subtypes across multiple categories of substance use in population-based samples. We examined the association between eating disorders and substance use in a large population-based sample.MethodFemale participants (n=13 297) were from the Swedish Twin Registry [Lichtenstein et al., Twin Research and Human Genetics (2006) 9, 875–882]. Substance use was examined in four defined groups – (1) anorexia nervosa (AN); (2) bulimia nervosa (BN); (3) AN and BN (ANBN); and (4) binge eating disorder (BED) as well as a referent group without eating disorder (no ED). Secondary analyses examined differences between restricting AN (RAN) and binge and/or purge AN (ANBP).ResultsIn general, eating disorders were associated with greater substance use relative to the referent. The AN group had significantly increased odds for all illicit drugs. Significant differences emerged across the RAN and ANBP groups for alcohol abuse/dependence, diet pills, stimulants, and polysubstance use with greater use in the ANBP group. Across eating disorder groups, (1) the BN and ANBN groups were more likely to report alcohol abuse/dependence relative to the AN group, (2) the ANBN group was more likely to report diet pill use relative to the AN, BN and BED groups, and (3) the BN group was more likely to report diet pill use relative to the no ED, AN and BED groups.ConclusionsEating disorders are associated with a range of substance use behaviors. Improved understanding of how they mutually influence risk could enhance understanding of etiology and prevention.

ASD, SUD and gender

2017 ◽  
Vol 41 (S1) ◽  
pp. s882-s883
Author(s):  
P.J.M. Van Wijngaarden-Cremers
Keyword(s):  
Gender Differences ◽  
Eating Disorders ◽  
Substance Use ◽  
Autism Spectrum ◽  
Substance Abuse Disorder ◽  
Co Morbidity ◽  
Spectrum Disorders ◽  
Competing Interest ◽  
And Gender ◽  
Very High

IntroductionAutism and substance use disorder (SUD) is not the co-morbidity that is commonly considered. Yet these conditions have more commonalities than one would suspect.ObjectiveWe will consider the evidence for co-morbidity between ASD and Addiction (Substance Use Disorders (SUD) and explore the influence of gender.MethodA pilot study of 80 admissions to an adult ASD unit will be presented.ResultsThe co-morbidity ASD and SUD in this study was very high (65% of the inpatients). There were no gender differences in prevalence in total but addiction to medication (32% in woman vs. none in man) and eating disorders (24% in women vs. 9% in man) was far more common in women whereas addiction to drugs (13% in man vs. none in women) was far more common in man.ConclusionsThere are clear indications that a possible co-morbidity of substance abuse disorder should be considered in cases of individuals with autism spectrum disorders. There are no gender differences in prevalence of co-morbidity ASD and SUD in total but addiction to medication and eating disorders seems to be much more common in women whereas addiction to drugs probably more common in man.Disclosure of interestThe author has not supplied his/her declaration of competing interest.

scholarly journals Remission, continuation and incidence of eating disorders during early pregnancy: a validation study in a population-based birth cohort

2012 ◽  
Vol 43 (8) ◽  
pp. 1723-1734 ◽  
Author(s):  
H. J. Watson ◽  
A. Von Holle ◽  
R. M. Hamer ◽  
C. Knoph Berg ◽  
L. Torgersen ◽  
...  
Keyword(s):  
Eating Disorders ◽  
Eating Disorder ◽  
Early Pregnancy ◽  
Training Sample ◽  
Population Based ◽  
Model Parameters ◽  
Calibration Model ◽  
Validation Sample ◽  
Internal Validation ◽  
Two Samples

BackgroundWe internally validated previously published rates of remission, continuation and incidence of broadly defined eating disorders during pregnancy in the Norwegian Mother and Child Cohort (MoBa) at the Norwegian Institute of Public Health.MethodA total of 77 267 pregnant women enrolled at 17 weeks gestation between 2001 and 2009 were split into a training sample (n = 41 243) from the version 2 dataset and a validation sample (n = 36 024) from the version 5 dataset who were not in the original study. Internal validation of original rate models involved fitting a calibration model to compare model parameters between the two samples and bootstrap estimates of bias in the entire version 5 dataset.ResultsRemission, continuation and incidence estimates remained stable. Pre-pregnancy prevalence estimates in the validation sample were: anorexia nervosa (AN; 0.1%), bulimia nervosa (BN; 1.0%), binge eating disorder (BED; 3.3%) and eating disorder not otherwise specified-purging disorder (EDNOS-P; 0.1%). In early pregnancy, estimates were: BN (0.2%), BED (4.8%) and EDNOS-P (<0.01%). Incident BN and EDNOS-P during pregnancy were rare. The highest rates were for full or partial remission for BN and EDNOS-P and continuation for BED.ConclusionsWe validated previously estimated rates of remission, continuation and incidence of eating disorders during pregnancy. Eating disorders, especially BED, during pregnancy were relatively common, occurring in nearly one in every 20 women. Pregnancy was a window of remission from BN but a window of vulnerability for BED. Training to detect eating disorders by obstetricians/gynecologists and interventions to enhance pregnancy and neonatal outcomes warrant attention.

Twelve-year course and outcome of bulimia nervosa

2004 ◽  
Vol 34 (8) ◽  
pp. 1395-1406 ◽  
Author(s):  
MANFRED M. FICHTER ◽  
NORBERT QUADFLIEG
Keyword(s):  
Eating Disorders ◽  
Anorexia Nervosa ◽  
Eating Disorder ◽  
Bulimia Nervosa ◽  
General Pattern ◽  
Prospective Longitudinal Study ◽  
End Of Treatment ◽  
Co Morbidity ◽  
Prospective Longitudinal

Background. Since little is known about the long-term course and outcome of bulimia nervosa, the authors designed a 12-year prospective longitudinal study with five cross-sectional assessments based on a large sample of consecutively treated females with bulimia nervosa (purging type) (BN-P).Method. One hundred and ninety-six females with BN-P were assessed (1) at the beginning of treatment, (2) at the end of treatment, (3) at 2-year follow-up, (4) at 6-year follow-up, and (5) at 12-year follow-up. In self-ratings as well as expert ratings based on interviews we assessed specific eating-disorder and general psychopathology.Results. The general pattern of results over time showed substantial improvement during treatment, slight (in most cases non-significant) decline during the first two years after the end of treatment, and further improvement and stabilization until 12-year follow-up. At that point the majority of patients (70·1%) showed no major DSM-IV eating disorder, 13·2% had eating disorders not otherwise specified, 10·1% had BN-P and 2% had died. Very few had undergone transition to anorexia nervosa or binge-eating disorders. Logistic regression analyses showed that psychiatric co-morbidity was the best and most stable predictor for eating-disorder outcome at 2, 6 and 12 years.Conclusions. Course and outcome of BN-P was generally more favourable than for anorexia nervosa.

scholarly journals Excess mortality associated with eating disorders: population-based cohort study

2020 ◽  
pp. 1-7
Author(s):  
Tomisin Iwajomo ◽  
Susan J. Bondy ◽  
Claire de Oliveira ◽  
Patricia Colton ◽  
Kathryn Trottier ◽  
...  
Keyword(s):  
Eating Disorders ◽  
Anorexia Nervosa ◽  
Cohort Study ◽  
Eating Disorder ◽  
Mortality Risk ◽  
Excess Mortality ◽  
Population Based ◽  
Cox Proportional Hazards ◽  
Years Of Life Lost ◽  
All Cause Mortality

Background Individuals with eating disorders have a high mortality risk. Few population-based studies have estimated this risk in eating disorders other than anorexia nervosa. Aims To investigate all-cause mortality in a population-based cohort of individuals who received hospital-based care for an eating disorder (anorexia nervosa, bulimia nervosa or eating disorder not otherwise specified) in Ontario, Canada. Method We conducted a retrospective cohort study of 19 041 individuals with an eating disorder from 1 January 1990 to 31 December 2013 using administrative healthcare data. The outcome of interest was death. Excess mortality was assessed using standardised mortality ratios (SMRs) and potential years of life lost (PYLL). Cox proportional hazards regression models were used to examine sociodemographic and medical comorbidities associated with greater mortality risk. Results The cohort had 17 108 females (89.9%) and 1933 males (10.1%). The all-cause mortality for the entire cohort was five times higher than expected compared with the Ontario population (SMR = 5.06; 95% CI 4.82–5.30). SMRs were higher for males (SMR = 7.24; 95% CI 6.58–7.96) relative to females (SMR = 4.59; 95% CI 4.34–4.85) overall, and in all age groups in the cohort. For both genders, the cohort PYLL was more than six times higher than the expected PYLL in the Ontario population. Conclusions Patients with eating disorders diagnosed in hospital settings experience five to seven times higher mortality rates compared with the overall population. There is an urgent need to understand the mortality risk factors to improve health outcomes among individuals with eating disorders.

Comparative Assessment of Cognitive Function and Mood Dynamics in Patients with Depression and Eating Disorders in the Process of Treatment

2017 ◽  
Vol 41 (S1) ◽  
pp. S285-S285
Author(s):  
I. Makhortova ◽  
O. Shiryaev
Keyword(s):  
Eating Disorders ◽  
Eating Disorder ◽  
Cognitive Function ◽  
Rating Scale ◽  
Co Morbidity ◽  
Icd 10 ◽  
Group 2 ◽  
Competing Interest ◽  
Clinically Significant ◽  
Group 1

Eating disorders of bulimic type are among the most common comorbidities with depression. The objective is to evaluate cognitive function and mood dynamics in patients with depression and eating disorders in pharmacotherapy. In total, 52 outpatients, who met criteria for “major depressive episode” (ICD-10), participated. The level of depression was estimated with Hamilton Depression rating scale (HAM-D) and cognitive function–Montreal Cognitive Assessment (MoCa). Sample was divided into two groups. Patients of group 1 also met criteria for eating disorder of bulimic type and patients of group 2 did not have any eating disorder. Treatment included standard doses of SSRI. Assessments were performed after 2, 4 and 8 weeks (D14, D30, D60). The level of HAM-D was significantly greater (P < 0.05) in eating disorders group (16.75 ± 2.83 in group 1; 13.04 ± 1.93 in group 2 at screening) and significance was preserved till D60 (9.39 ± 2.54 in group 1; 6.32 ± 1.27 in group 2 at D60). Clinically significant antidepressive effect was revealed faster in group 2 (at D7) compared to group 1 (at D14). Overall score of MoCA was significantly lower (P < 0.05) in eating disorders group (20.33 ± 0.54 in group 1; 23.43 ± 2.32 in group 2 at screening) at all stages of treatment (23.39 ± 0.78 in group 1; 26.96 ± 3.27 in group 2 at D60) and it reached normal range (25 and more) only in group 2 at D60. Significant change from screening was revealed at D30 at group 2 and at D60 at group 1.ConclusionEating disorder have an impact on SSRI treatment efficacy including antidepressive and procognitive effects. It is necessary to reveal eating disorders as a co-morbidity in patients with depression.Disclosure of interestThe authors have not supplied their declaration of competing interest.

scholarly journals Adult attention-deficit/hyperactivity disorder and its association with substance use and substance use disorders in young men

2015 ◽  
Vol 25 (3) ◽  
pp. 255-266 ◽  
Author(s):  
N. Estévez ◽  
M. Dey ◽  
D. Eich-Höchli ◽  
S. Foster ◽  
G. Gmel ◽  
...  
Keyword(s):  
Attention Deficit Hyperactivity Disorder ◽  
Substance Use ◽  
Substance Use Disorders ◽  
Attention Deficit ◽  
Illicit Drugs ◽  
Adult Adhd ◽  
Young Men ◽  
Use Patterns ◽  
Hyperactivity Disorder ◽  
Co Morbidity

Background.Functional and mental health impairments that adults with attention-deficit/hyperactivity disorder (ADHD) experience may be exacerbated by regular substance use and co-morbidity with substance use disorders (SUD). This may be especially true during young adulthood, which represents a critical stage of life associated with increased substance use and associated problems. However, previous studies investigating the association between ADHD and substance use and SUD have demonstrated inconsistent results, probably due to methodological limitations (e.g., small and non-representative samples). Thus, the relationship of ADHD with substance use and related disorders remains unclear. The aim of the present study was to examine the association between ADHD and both the use of licit and illicit substances and the presence of SUD in a large, representative sample of young men.Method.The sample included 5677 Swiss men (mean age 20 ± 1.23 years) who participated in the Cohort Study on Substance Use Risk Factors (C-SURF). ADHD was assessed using the adult ADHD Self Report Screener (ASRS). The association between ADHD and substance use and SUD was assessed for alcohol, nicotine, cannabis and other illicit drugs, while controlling for socio-demographic variables and co-morbid psychiatric disorders (i.e., major depression (MD) and anti-social personality disorder (ASPD)).Results.Men with ADHD were more likely to report having used nicotine, cannabis and other illicit drugs at some time in their life, but not alcohol. ADHD was positively associated with early initiation of alcohol, nicotine and cannabis use, the risky use of these substances, and the presence of alcohol use disorders, and nicotine and cannabis dependence. Additionally, our analyses revealed that these patterns are also highly associated with ASPD. After adjusting for this disorder, the association between ADHD and licit and illicit substance use and the presence of SUDs was reduced, but remained significant.Conclusions.Our findings suggest that adult ADHD is significantly associated with a propensity to experiment with licit and illicit substances, especially at earlier ages, to exhibit risky substance use patterns, and to subsequently develop SUDs. Preventive strategies that include early intervention and addressing co-morbidity with ASPD may be crucial to reducing substance use and the development of pathological substance use patterns in young men affected by ADHD and, thus, helping to prevent further illness burden later in life.

Identification and validation of mixed anxiety–depression

2015 ◽  
Vol 45 (14) ◽  
pp. 3075-3084 ◽  
Author(s):  
J. M. Hettema ◽  
S. H. Aggen ◽  
T. S. Kubarych ◽  
M. C. Neale ◽  
K. S. Kendler
Keyword(s):  
Latent Class ◽  
Large Population ◽  
Population Based ◽  
Prior History ◽  
Class Model ◽  
Co Morbidity ◽  
The Stability ◽  
Low Prevalence ◽  
Anxiety Depression ◽  
Symptom Criteria

Background.Mixed anxiety–depression (MAD) has been under scrutiny to determine its potential place in psychiatric nosology. The current study sought to investigate its prevalence, clinical characteristics, course and potential validators.Method.Restricted latent-class analyses were fit to 12-month self-reports of depression and anxiety symptom criteria in a large population-based sample of twins. Classes were examined across an array of relevant indicators (demographics, co-morbidity, adverse life events, clinical significance and twin concordance). Longitudinal analyses investigated the stability of, and transitions between, these classes for two time periods approximately 1.5 years apart.Results.In all analyses, a class exhibiting levels of MAD symptomatology distinctly above the unaffected subjects yet having low prevalence of either major depression (MD) or generalized anxiety disorder (GAD) was identified. A restricted four-class model, constraining two classes to have no prior disorder history to distinguish residual or recurrent symptoms from new onsets in the last year, provided an interpretable classification: two groups with no prior history that were unaffected or had MAD and two with prior history having relatively low or high symptom levels. Prevalence of MAD was substantial (9–11%), and subjects with MAD differed quantitatively but not qualitatively from those with lifetime MD or GAD across the clinical validators examined.Conclusions.Our findings suggest that MAD is a commonly occurring, identifiable syndromal subtype that warrants further study and consideration for inclusion in future nosologic systems.

Sign in / Sign up

Export Citation Format

Share Document